Global DNA Vaccine Market Hits $960 Million in 2025 with 4.5% CAGR

DNA vaccine market was valued at $960 million in 2025 and is projected to reach $1,475 million by 2035, growing at a CAGR of 4.5% during the forecast Period (2026-2035). The global DNA vaccine market is driven by increasing demand from pharmaceutical companies, biotechnology firms, and public health institutions, where rapid development capability, genetic stability, scalability, and targeted immune response are important technical requirements. DNA vaccines are applied in infectious disease prevention, oncology research, and veterinary medicine to support immunization programs and disease control initiatives.

Browse the full report description of “DNA Vaccine Market Size, Share & Trends Analysis By Type (Animal DNA Vaccine and Human DNA Vaccine), By Technology (Plasmid DNA Vaccines Technology and Plasmid DNA Delivery Technology), By Application (Oncology, Infectious Diseases, and Others), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/dna-vaccines-market

The DNA vaccine market is influenced by rising investments in genetic and molecular research, government funding for vaccine development, and the need for adaptable vaccine platforms. Regulatory authorities and public health organizations are supporting the development of next-generation vaccines that can be produced efficiently and modified in response to emerging pathogens. These factors have contributed to expanded clinical research and regulatory review of DNA-based vaccine technologies.

In the United States, regulatory frameworks under the Food and Drug Administration (FDA) and research support from agencies such as the National Institutes of Health (NIH) guide the development and evaluation of DNA vaccines through established biologics approval pathways and public research programs. These institutions provide guidance for nucleic acid-based vaccines and support clinical studies for applications in infectious diseases, cancer immunotherapy, and biodefense.

Key Innovators Driving DNA Vaccine Development

The key players in the global DNA vaccine market include GlaxoSmithKline plc, Merck and Co., Pfizer Inc., and Roche Diagnostics, among others. These companies are engaged in the development of DNA-based vaccine platforms for infectious diseases, oncology, and immunotherapy applications, using plasmid DNA technologies to enable in-vivo protein expression and immune system activation.

• In February 2025, IMUNON, Inc. announced new immunogenicity and safety data from its Phase 1 clinical trial of IMNN-101, an investigational DNA plasmid vaccine based on its proprietary PlaCCine® technology platform, targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen. The Phase 1 results showed that the vaccine induced neutralizing antibody responses and demonstrated an acceptable safety profile in healthy volunteers, supporting continued clinical development of the DNA vaccine candidate.
• In January 2025, INOVIO Pharmaceuticals announced interim results from its Phase 1 proof-of-concept clinical trial of DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. The study demonstrated sustained in-vivo antibody expression for up to 72 weeks with stable safety and immunogenicity profiles, supporting the use of DNA delivery platforms for next-generation vaccine and immunotherapy development.

 Market Coverage

• The market number available for – 2026-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • by Type 
  • by Technology
  • by Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - GlaxoSmithKline plc, Merck and Co., Pfizer Inc., and Roche Diagnostics, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

DNA vaccine market Report Segment

By Type

• Animal DNA Vaccine
• Human DNA Vaccine

By Technology

• Plasmid DNA Vaccines Technology
• Plasmid DNA Delivery Technology

By Application

• Oncology
• Infectious Diseases
• Others

DNA vaccine market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dna-vaccines-market